ELREXFIO

This brand name is authorized in Austria, Estonia, France, Croatia, Lithuania, Romania, United States

Active ingredients

The drug ELREXFIO contains one active pharmaceutical ingredient (API):

1 Elranatamab UNII L0HR9A577V - ELRANATAMAB

Elranatamab is a bi-specific T-cell engaging antibody that binds CD3-epsilon on T-cells and B-cell maturation antigen (BCMA) on plasma cells, plasmablasts, and multiple myeloma cells. Binding of elranatamab to BCMA on tumour cells and CD3 on T-cells is independent of native T-cell receptor (TCR) specificity or reliance on major histocompatibility (MHC) Class 1 molecules. Elranatamab activated T-cells, led to proinflammatory cytokine release, and resulted in multiple myeloma cell lysis. Read about Elranatamab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ELREXFIO Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR
ELREXFIO Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX32		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX32

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3062933, 3062944
Country: FR	Base de données publique des médicaments	Identifier(s): 65312065
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1098434, 1098435
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W70072001, W70072002
Country: US	FDA, National Drug Code	Identifier(s): 0069-2522, 0069-4494, 63539-252